CL2015002632A1 - Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado - Google Patents
Aglomerados respirables de partículas de vehículo porosas y fármaco micronizadoInfo
- Publication number
- CL2015002632A1 CL2015002632A1 CL2015002632A CL2015002632A CL2015002632A1 CL 2015002632 A1 CL2015002632 A1 CL 2015002632A1 CL 2015002632 A CL2015002632 A CL 2015002632A CL 2015002632 A CL2015002632 A CL 2015002632A CL 2015002632 A1 CL2015002632 A1 CL 2015002632A1
- Authority
- CL
- Chile
- Prior art keywords
- breathable
- present
- vehicle particles
- agglomerates
- micronized drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784842P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002632A1 true CL2015002632A1 (es) | 2016-03-28 |
Family
ID=50478894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002632A CL2015002632A1 (es) | 2013-03-14 | 2015-09-11 | Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9452139B2 (enExample) |
| EP (1) | EP2968570A1 (enExample) |
| JP (1) | JP6374414B2 (enExample) |
| KR (1) | KR20150129716A (enExample) |
| CN (1) | CN105188757B (enExample) |
| AU (2) | AU2014229265A1 (enExample) |
| BR (1) | BR112015021814A2 (enExample) |
| CA (1) | CA2905615A1 (enExample) |
| CL (1) | CL2015002632A1 (enExample) |
| EA (1) | EA201591729A1 (enExample) |
| GT (1) | GT201500295A (enExample) |
| HK (1) | HK1212616A1 (enExample) |
| IL (1) | IL240963A (enExample) |
| MA (1) | MA38397A1 (enExample) |
| MX (1) | MX2015012814A (enExample) |
| PE (1) | PE20151655A1 (enExample) |
| PH (1) | PH12015501882A1 (enExample) |
| SA (1) | SA515361055B1 (enExample) |
| SG (1) | SG11201506397QA (enExample) |
| TN (1) | TN2015000395A1 (enExample) |
| WO (1) | WO2014141135A1 (enExample) |
| ZA (1) | ZA201505768B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1993360T3 (pl) | 2005-12-28 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| EP3045452A1 (en) | 2010-04-22 | 2016-07-20 | Vertex Pharmaceuticals Inc. | Process of producing cycloalkylcarboxamido-indole compounds |
| JP2016506947A (ja) * | 2013-01-31 | 2016-03-07 | プロソニックス リミテッド | 吸入療法において使用するのに適する多成分結晶粒子を含む医薬組成物 |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| KR20160137543A (ko) * | 2014-03-27 | 2016-11-30 | 노파르티스 아게 | 활성 약제 성분의 흡입을 위한 분무-건조되는 수-중-유-중-고체 분산액 |
| PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| ES2702288T3 (es) | 2014-10-07 | 2019-02-28 | Vertex Pharma | Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística |
| WO2016142708A2 (en) * | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
| US10423736B2 (en) * | 2015-08-28 | 2019-09-24 | University Of British Columbia | Methods and systems for simulating hydrodynamics in gas-solid fluidized beds |
| EP3335699A1 (en) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| WO2020247376A1 (en) * | 2019-06-03 | 2020-12-10 | Cai Gu Huang | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| CN114206137A (zh) * | 2019-08-15 | 2022-03-18 | 雅培制药有限公司 | 使用微粉化的营养粉末制造方法和粉末组合物 |
| BR112022020732A2 (pt) * | 2020-04-13 | 2022-12-20 | Univ Basel | Método de dosagem e tratamento de pacientes com um psicodélico, método para determinar uma dose de um psicodélico para um indivíduo, método para definir doses terapêuticas de um psicodélico em ensaios clínicos, método para tratar afecções psiquiátricas em um indivíduo, métodos de terapia, e método para monitorar indivíduos para depressão após tratamento com lsd |
| CN114344285B (zh) * | 2020-10-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 改良的可吸入团聚物 |
| TW202237102A (zh) * | 2020-12-11 | 2022-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 用於肺部遞送的藥物組合物 |
| CN113318097A (zh) * | 2021-04-29 | 2021-08-31 | 珠海瑞思普利医药科技有限公司 | 一种抗特发性肺纤维化的粉雾剂及制备方法 |
| US12534460B2 (en) | 2021-04-30 | 2026-01-27 | Mind Medicine, Inc. | LSD salt crystal forms |
| IL310569A (en) | 2021-08-19 | 2024-03-01 | Mind Medicine Inc | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| CN116785246A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 一种药物微球及含其的气雾剂 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| WO2025256638A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海济昀生物科技有限公司 | 一种混悬型三联吸入气雾剂组合物及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| EP0057401B1 (en) | 1981-02-02 | 1984-08-01 | Schering Corporation | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| ATE137675T1 (de) | 1991-06-26 | 1996-05-15 | Schering Corp | Inhalator für medikamente in pulverform |
| KR0163472B1 (ko) | 1992-12-18 | 1998-11-16 | 에릭 에스. 딕커 | 분말 약품용 흡입기 |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| PL187750B1 (pl) | 1994-09-21 | 2004-09-30 | Nektar Therapeutics | Sposób i urządzenie do wytwarzania aerozolu ze sproszkowanego leku |
| DE69617754T2 (de) | 1996-01-03 | 2002-08-08 | Glaxo Group Ltd., Greenford | Inhalator |
| CZ298885B6 (cs) | 1996-02-21 | 2008-03-05 | Schering Corporation | Inhalátor práškových léku |
| PT1371645E (pt) | 1996-11-11 | 2013-05-21 | Meda Pharma Gmbh & Co Kg | Utilização de (3s,2¿r)-glicopirrónio como produto farmacêutico |
| US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| PT1131059E (pt) | 1998-11-13 | 2003-07-31 | Jago Res Ag | Po seco para inalacao |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| ES2265944T3 (es) | 1999-05-28 | 2007-03-01 | Nektar Therapeutics | Aparato y procedimiento para aerosolizar una composicion farmaceutica en polvo. |
| US20010029947A1 (en) | 1999-12-17 | 2001-10-18 | Steve Paboojian | Receptacles to facilitate the extraction of powders |
| US7069929B2 (en) | 2000-02-01 | 2006-07-04 | Quadrant Technologies Limited | Dry powder inhaler |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| AU6124601A (en) | 2000-05-10 | 2001-11-20 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| AU2003287132B2 (en) | 2002-12-13 | 2009-03-12 | Adagit | Pharmaceutical porous particles |
| PL1610850T3 (pl) | 2003-04-09 | 2012-11-30 | Novartis Ag | Urządzenie rozpylające z osłoną wlotu powietrza |
| GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| AU2005216061B2 (en) | 2004-02-24 | 2010-05-27 | Microdose Therapeutx, Inc. | Synthetic jet based medicament delivery method and apparatus |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| SI2044025T1 (sl) | 2006-06-30 | 2013-01-31 | Novartis Ag | Kinolinonski derivati in njihovi farmacevtski sestavki |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| CA2667225C (en) | 2006-10-25 | 2015-06-09 | Novartis Ag | Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices |
| KR101621986B1 (ko) | 2008-05-15 | 2016-05-17 | 노파르티스 아게 | 플루오로퀴놀론의 폐 전달 |
| ES2617680T3 (es) | 2009-04-09 | 2017-06-19 | Novartis Ag | Proceso para la preparación de sales de pirrolidinio |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| PH12012501792A1 (en) | 2010-04-01 | 2012-12-10 | Chiesi Farm Spa | Process for preparing carrier particles for dry powders for inhalation |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| US9452139B2 (en) * | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
-
2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/en not_active Withdrawn
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Ceased
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en not_active Ceased
- 2014-03-13 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
-
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
-
2016
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
-
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160354388A1 (en) | 2016-12-08 |
| SG11201506397QA (en) | 2015-09-29 |
| EP2968570A1 (en) | 2016-01-20 |
| IL240963A0 (en) | 2015-11-30 |
| JP2016512494A (ja) | 2016-04-28 |
| BR112015021814A2 (pt) | 2017-07-18 |
| PE20151655A1 (es) | 2015-11-26 |
| AU2014229265A1 (en) | 2015-09-03 |
| CN105188757A (zh) | 2015-12-23 |
| CN105188757B (zh) | 2019-04-30 |
| HK1212616A1 (zh) | 2016-06-17 |
| US20140302147A1 (en) | 2014-10-09 |
| AU2017203258B2 (en) | 2019-06-20 |
| EA201591729A1 (ru) | 2016-05-31 |
| TN2015000395A1 (en) | 2017-01-03 |
| US9452139B2 (en) | 2016-09-27 |
| KR20150129716A (ko) | 2015-11-20 |
| MA38397A1 (fr) | 2018-01-31 |
| SA515361055B1 (ar) | 2016-11-13 |
| JP6374414B2 (ja) | 2018-08-15 |
| ZA201505768B (en) | 2017-03-29 |
| US9744178B2 (en) | 2017-08-29 |
| PH12015501882A1 (en) | 2015-12-07 |
| WO2014141135A1 (en) | 2014-09-18 |
| MX2015012814A (es) | 2016-02-03 |
| IL240963A (en) | 2017-05-29 |
| CA2905615A1 (en) | 2014-09-18 |
| AU2017203258A1 (en) | 2017-06-08 |
| GT201500295A (es) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002632A1 (es) | Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado | |
| CL2016000735A1 (es) | Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc. | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| DOP2015000100A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| CU20160087A7 (es) | Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen | |
| MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| SV2016005206A (es) | Derivados novedosos de amino pirimidina | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| BR112013008005A2 (pt) | composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| CL2016000028A1 (es) | Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación | |
| AR098333A1 (es) | Una composición en forma de polvo | |
| BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
| BR112014017481A8 (pt) | formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
| BR112015020443A2 (pt) | desamorfização de formulações secadas por atomização via mistura por atomização |